Moderna (MRNA) 'remains comfortable' with Covid vaccine guidance range after Pfizer slashes forecast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Moderna reaffirms annual COVID vaccine sales forecast
October 16, 2023 9:17 AM EDT(Reuters) - Moderna on Monday reaffirmed its forecast of $6 billion to $8 billion in COVID vaccine sales for the year, after rival Pfizer slashed forecast for its vaccine last week.
Moderna said it will have "improved visibility" about the expected U.S. market size for vaccines after observing trends through October... More
Moderna (MRNA) remains comfortable with its guided range for FY23 Covid vaccine sales
October 16, 2023 9:03 AM EDT(Updated - October 16, 2023 9:04 AM EDT)
Moderna (NASDAQ: MRNA) disclosed:
On October 16, 2023, Moderna, Inc. (the Company) provided the following statement on the Statements and Perspectives webpage of its Investor Relations... More
Moderna (MRNA) remains comfortable with $6-8B in 2023 COVID vaccine revenue
October 16, 2023 9:02 AM EDTModerna (NASDAQ: MRNA) provided the following statement on the Statements and Perspectives webpage of its Investor Relations website:
Moderna remains comfortable that its guided wide range of $6 billion to $8 billion for anticipated revenues from sale of its COVID-19 vaccine for the full year 2023,... More
Apple, Nvidia and Pfizer fall premarket; Lululemon rises
October 16, 2023 8:20 AM EDTInvesting.com -- U.S. futures edged higher Monday, at the start of a week that sees the quarterly earnings season ramp up.
Here are some of the biggest premarket U.S. stock movers today:
Rite Aid (NYSE: RAD) stock rose 4.5%, rebounding after Fridays 17% drop, after the... More
Moderna (MRNA) option IV flat
October 16, 2023 4:59 AM EDTModerna (NASDAQ: MRNA) 30-day option implied volatility is at 56; compared to its 52-week range of 40 to 77 into Pfizer (PFE) cuts FY23 financial view.
... More